A.M. and S.K. contributed equally to this project and share first authorship.

Introduction {#bju14417-sec-0001}
============

Bladder cancer (BCa) is the fourth most commonly diagnosed malignancy in men, with significant morbidity and mortality worldwide [1](#bju14417-bib-0001){ref-type="ref"}. In western countries, \~70% of patients with BCa are diagnosed with non‐muscle‐invasive BCa (NMIBC) [2](#bju14417-bib-0002){ref-type="ref"}. Transurethral resection of the bladder tumour (TURBT) is necessary for the diagnosis, risk stratification and treatment of patients with NMIBC; however, up to 61% and 17% of patients who undergo TURBT and adjuvant treatment with BCG, respectively, for high‐risk cT1 BCa experience disease recurrence or progression to carcinoma invading the bladder muscle (MIBC) within the first year [2](#bju14417-bib-0002){ref-type="ref"}, [3](#bju14417-bib-0003){ref-type="ref"}. Identification of patients with NMIBC who are at high risk of experiencing progression to MIBC would allow selection for intensified therapy such as early radical cystectomy (RC) or inclusion in clinical trials of new therapies.

Lymphovascular invasion (LVI) is a crucial step in the initiation of tumour dissemination and metastasis [4](#bju14417-bib-0004){ref-type="ref"}. Although LVI has been established as a feature of biologically and clinically aggressive disease in patients treated with RC [5](#bju14417-bib-0005){ref-type="ref"}, [6](#bju14417-bib-0006){ref-type="ref"}, [7](#bju14417-bib-0007){ref-type="ref"}, [8](#bju14417-bib-0008){ref-type="ref"}, its role at TUR is not yet clear. The results from a previous meta‐analysis suggested an increased risk of pathological upstaging and poor clinical outcomes in patients with LVI at TURBT [9](#bju14417-bib-0009){ref-type="ref"}; however, the selection criteria included all studies regardless of the patients' tumour stage. Moreover, new studies have added further data with which to analyse the prognostic impact of LVI at TUR in patients with organ‐confined BCa [10](#bju14417-bib-0010){ref-type="ref"}, [11](#bju14417-bib-0011){ref-type="ref"}, [12](#bju14417-bib-0012){ref-type="ref"}, [13](#bju14417-bib-0013){ref-type="ref"}, [14](#bju14417-bib-0014){ref-type="ref"}, [15](#bju14417-bib-0015){ref-type="ref"}, [16](#bju14417-bib-0016){ref-type="ref"}, [17](#bju14417-bib-0017){ref-type="ref"}, [18](#bju14417-bib-0018){ref-type="ref"}.

The aim of the present study was to perform a systematic review and meta‐analysis to assess the role of LVI in TUR specimens, regardless of tumour stage, to investigate its prognostic impact on disease recurrence and progression in patients with NMIBC, and to assess its predictive value for upstaging at RC in patients with clinically organ‐confined (cT1--2) disease.

Evidence Acquisition {#bju14417-sec-0002}
--------------------

Table [S1](#bju14417-sup-0004){ref-type="supplementary-material"} shows a completed Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) 2015 checklist, which clearly describes the methodology of the review [19](#bju14417-bib-0019){ref-type="ref"}. The protocol has also been registered in the International Prospective Register of Systematic Reviews database (PROSPERO: CRD42018084876).

Literature Search {#bju14417-sec-0003}
-----------------

A systematic review and meta‐analysis of the English‐language literature was performed according to the PRISMA statement and the Cochrane Handbook for Systematic Reviews of Interventions [20](#bju14417-bib-0020){ref-type="ref"}, [21](#bju14417-bib-0021){ref-type="ref"} **.** The MEDLINE, EMBASE and Cochrane Library were systematically searched on 9 August 2017 to identify studies published between January 2007 and August 2017 that investigated the impact of LVI in TUR specimens on oncological outcomes in patients with urothelial BCa. After a first screening based on study title and abstract, all papers were assessed based on full text and excluded with reasons when inappropriate. A further check of the appropriateness of the papers based on full‐text revision was performed after data extraction. Two reviewers (A.M. and S.K.) carried out this process independently. Disagreements were solved by a third party (B.F.). The following string terms were used: ((('bladder') AND ('cancer' OR 'urothelial carcinoma' OR 'urothelial neoplasm' OR 'carcinoma' OR 'transitional cell carcinoma')) AND ('TUR' OR 'TURB' OR 'TRANSURETHRAL RESECTION')) AND ('LVI' OR 'lymphovascular invasion' OR 'lymphatic invasion' OR 'vascular invasion'). The process used to identify articles is summarized in Fig. [1](#bju14417-fig-0001){ref-type="fig"}. Disease recurrence, disease progression and upstaging were the primary outcomes of interest.

![Flow chart for the article selection process. LVI, lymphovascular invasion; RC, radical cystectomy; UC, urothelial carcinoma.](BJU-123-11-g001){#bju14417-fig-0001}

Eligibility Criteria {#bju14417-sec-0004}
--------------------

As proposed by the PRISMA guidelines, we used the Population, Intervention, Comparator, Outcome and Study design approach to specify the eligibility criteria: studies were considered eligible if patients with LVI in BCa (population) treated with TUR with or without RC (intervention) were compared with patients without LVI (comparator) to investigate the prognostic value of LVI on disease recurrence, progression and upstaging (outcomes) in non‐randomized observation or cohort studies.

### Inclusion and Exclusion Criteria for the Systematic Review {#bju14417-sec-0005}

After article selection according to the eligibility criteria, the following types of study were excluded: review articles; editorials; commentaries; papers written in languages other than English; meeting abstracts; replies from authors; and case reports. If multiple articles published by the same author or group and based on similar patient cohorts were found, only the paper with the largest cohort was included. For the purposes of the present study, all eligible studies were included in the systematic review, regardless of the clinical stage involved.

### Inclusion and Exclusion Criteria for the Meta‐Analysis {#bju14417-sec-0006}

The studies selected for the systematic review were then screened for the quantitative analysis. Of these, studies analysing patients with ≤cT1 (cTa‐Tis‐T1) stage disease were included in the meta‐analysis of the prognostic impact of LVI at TUR on disease recurrence and progression. Studies analysing patients with organ‐confined (≤cT2) disease and subsequently treated with RC were included in a meta‐analysis of the prognostic impact of LVI at TUR on upstaging at RC.

Data Extraction {#bju14417-sec-0007}
---------------

After full‐text evaluation, data were independently extracted by two authors (A.M. and S.K.) for further assessment of qualitative and quantitative evidence synthesis. All extracted variables were crosschecked to ensure their reliability. We recorded the baseline characteristics of the included participants, the use of peri‐operative chemotherapy and the median/mean follow‐up duration. Subsequently, the hazard ratios (HRs) and 95% confidence intervals (CIs) of LVI associated with each outcome were retrieved. Furthermore, we searched for methods and important confounders to establish comparability. All discrepancies regarding data extraction were resolved by consensus or finally decided on by the senior author (S.F.S.).

Statistical Analysis {#bju14417-sec-0008}
--------------------

Because of the observational nature of the included studies, we extracted the adjusted HR and odds ratio with 95% CI for cumulative effect size calculation from multivariable Cox regression analysis (for recurrence and progression outcomes) and logistic regression analysis (for upstaging outcome), respectively. Studies reporting only Kaplan--Meier log‐rank or univariable analyses were not considered for the meta‐analysis. Effect summary estimation methods were not used in these cases as a high level of additional selection bias would have been introduced. Statistical pooling of effect measures was based on the level of heterogeneity among studies, which was assessed with the Cochrane *Q* test and *I* ^2^ statistic. Significant heterogeneity was indicated by a *P* value \<0.05 in Cochrane *Q* tests and a ratio \>50% in *I* ^2^ statistics, which led to the use of random‐effect models according to the DerSimonian and Laird method [22](#bju14417-bib-0022){ref-type="ref"}, [23](#bju14417-bib-0023){ref-type="ref"}, [24](#bju14417-bib-0024){ref-type="ref"}. When these tests were negative for heterogeneity, fixed‐effect models were chosen for calculation of pooled HRs through the inverse‐variance method. Publication biases including small‐study effect were evaluated by visual inspection of funnel plots for all assessed comparisons. Statistical analyses were performed using [stata]{.smallcaps}/[mp]{.smallcaps} 14.2 (Stata Corp., College Station, TX, USA).

Risk of Bias {#bju14417-sec-0009}
------------

The risk‐of‐bias assessment is reported in Tables [S2](#bju14417-sup-0005){ref-type="supplementary-material"}, [S3](#bju14417-sup-0006){ref-type="supplementary-material"}, [S4](#bju14417-sup-0007){ref-type="supplementary-material"}. The risk‐of‐bias evaluation of included studies was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions for including non‐randomized studies [25](#bju14417-bib-0025){ref-type="ref"}, [26](#bju14417-bib-0026){ref-type="ref"}. Because of the inclusion of only non‐randomized comparative studies, risk of bias was determined by examining the risk of preassigned confounders. The main confounding factors were identified as the most important prognostic factors affecting disease recurrence, progression and upstaging. For this purpose, the Risk Of Bias In Non‐randomised Studies ‐ of Interventions (ROBINS‐I) was used for evaluating risk of bias in estimates of the comparative effectiveness of interventions from studies that did not use randomization to allocate units to comparison groups [27](#bju14417-bib-0027){ref-type="ref"}. The ROBINS‐I tool was used for each of the three outcomes analysed. The presence of confounders was determined by consensus between A.M. and B.F.

Evidence Synthesis {#bju14417-sec-0010}
==================

Study Selection {#bju14417-sec-0011}
---------------

We identified a total of 236 articles from the search query and five from the reference lists. Overall 130 articles were excluded after title and abstract screening and 78 after full‐text evaluation. The remaining 33 articles were included in the systematic review. The flow chart of the study selection process is shown in Fig. [1](#bju14417-fig-0001){ref-type="fig"}.

Study Population {#bju14417-sec-0012}
----------------

Study characteristics are reported in Table [1](#bju14417-tbl-0001){ref-type="table"} [10](#bju14417-bib-0010){ref-type="ref"}, [11](#bju14417-bib-0011){ref-type="ref"}, [12](#bju14417-bib-0012){ref-type="ref"}, [13](#bju14417-bib-0013){ref-type="ref"}, [14](#bju14417-bib-0014){ref-type="ref"}, [15](#bju14417-bib-0015){ref-type="ref"}, [16](#bju14417-bib-0016){ref-type="ref"}, [17](#bju14417-bib-0017){ref-type="ref"}, [18](#bju14417-bib-0018){ref-type="ref"}, [28](#bju14417-bib-0028){ref-type="ref"}, [29](#bju14417-bib-0029){ref-type="ref"}, [30](#bju14417-bib-0030){ref-type="ref"}, [31](#bju14417-bib-0031){ref-type="ref"}, [32](#bju14417-bib-0032){ref-type="ref"}, [33](#bju14417-bib-0033){ref-type="ref"}, [34](#bju14417-bib-0034){ref-type="ref"}, [35](#bju14417-bib-0035){ref-type="ref"}, [36](#bju14417-bib-0036){ref-type="ref"}, [37](#bju14417-bib-0037){ref-type="ref"}, [38](#bju14417-bib-0038){ref-type="ref"}, [39](#bju14417-bib-0039){ref-type="ref"}, [40](#bju14417-bib-0040){ref-type="ref"}, [41](#bju14417-bib-0041){ref-type="ref"}, [42](#bju14417-bib-0042){ref-type="ref"}, [43](#bju14417-bib-0043){ref-type="ref"}, [44](#bju14417-bib-0044){ref-type="ref"}, [45](#bju14417-bib-0045){ref-type="ref"}, [46](#bju14417-bib-0046){ref-type="ref"}, [47](#bju14417-bib-0047){ref-type="ref"}, [48](#bju14417-bib-0048){ref-type="ref"}, [49](#bju14417-bib-0049){ref-type="ref"}, [50](#bju14417-bib-0050){ref-type="ref"}, [51](#bju14417-bib-0051){ref-type="ref"}. The 33 studies included 6194 patients treated with TUR with or without RC. The population examined was from the USA/Canada in 13 studies, Europe in 10 studies and Asia in 10 studies. All the studies had a retrospective design. LVI definition was provided in 16 studies (48.5%) and was found in 1 069 of 6194 patients (17.3%). Pathological characteristics are reported in Table [2](#bju14417-tbl-0002){ref-type="table"} [10](#bju14417-bib-0010){ref-type="ref"}, [11](#bju14417-bib-0011){ref-type="ref"}, [12](#bju14417-bib-0012){ref-type="ref"}, [13](#bju14417-bib-0013){ref-type="ref"}, [14](#bju14417-bib-0014){ref-type="ref"}, [15](#bju14417-bib-0015){ref-type="ref"}, [16](#bju14417-bib-0016){ref-type="ref"}, [17](#bju14417-bib-0017){ref-type="ref"}, [18](#bju14417-bib-0018){ref-type="ref"}, [28](#bju14417-bib-0028){ref-type="ref"}, [29](#bju14417-bib-0029){ref-type="ref"}, [30](#bju14417-bib-0030){ref-type="ref"}, [31](#bju14417-bib-0031){ref-type="ref"}, [32](#bju14417-bib-0032){ref-type="ref"}, [33](#bju14417-bib-0033){ref-type="ref"}, [34](#bju14417-bib-0034){ref-type="ref"}, [35](#bju14417-bib-0035){ref-type="ref"}, [36](#bju14417-bib-0036){ref-type="ref"}, [37](#bju14417-bib-0037){ref-type="ref"}, [38](#bju14417-bib-0038){ref-type="ref"}, [39](#bju14417-bib-0039){ref-type="ref"}, [40](#bju14417-bib-0040){ref-type="ref"}, [41](#bju14417-bib-0041){ref-type="ref"}, [42](#bju14417-bib-0042){ref-type="ref"}, [43](#bju14417-bib-0043){ref-type="ref"}, [44](#bju14417-bib-0044){ref-type="ref"}, [45](#bju14417-bib-0045){ref-type="ref"}, [46](#bju14417-bib-0046){ref-type="ref"}, [47](#bju14417-bib-0047){ref-type="ref"}, [48](#bju14417-bib-0048){ref-type="ref"}, [49](#bju14417-bib-0049){ref-type="ref"}, [50](#bju14417-bib-0050){ref-type="ref"}, [51](#bju14417-bib-0051){ref-type="ref"}. Overall, 62% of patients had NMIBC, 32% had cT2 stage and 6% had cT3--4 stage. In 19 studies, only patients with NMIBC were analysed (*n* = 2 941) and LVI was detected in 15% of these patients. Extravesical disease and node involvement were reported in 633/1715 (36.9%) and 371/1537 patients (24.2%) subsequently treated after RC, respectively.

###### 

Characteristics of the eligible studies included in the systematic review

  First author of study and year                                                                         Country      Recruitment period   No. of patients   LVI, %   Definition of LVI   NOS   Main treatment
  ------------------------------------------------------------------------------------------------------ ------------ -------------------- ----------------- -------- ------------------- ----- ----------------
  Andius P (2007) [28](#bju14417-bib-0028){ref-type="ref"}                                               Sweden       1987--1989           121               9.9      Yes                 5     TUR
  Kassouf W (2007) [29](#bju14417-bib-0029){ref-type="ref"}                                              USA          1990--2005           120               31.7     No                  6     RC
  Herr HW (2008) [30](#bju14417-bib-0030){ref-type="ref"}                                                USA          1995--2001           63                55.6     No                  8     TUR
  Weizer AZ (2009) [31](#bju14417-bib-0031){ref-type="ref"}                                              USA          1995--2007           95                12.6     No                  6     RC
  Cho KS (2009) [32](#bju14417-bib-0032){ref-type="ref"}                                                 Korea        2001--2007           118               28.0     Yes                 7     TUR
  Streeper N (2009) [33](#bju14417-bib-0033){ref-type="ref"}                                             USA          1995--2005           103               67.0     Yes                 4     RC
  Seo HK (2010) [34](#bju14417-bib-0034){ref-type="ref"}                                                 Korea        2001--2006           129               3.9      No                  4     TUR
  Font A (2011) [35](#bju14417-bib-0035){ref-type="ref"}                                                 Spain        1994--2007           98                14.3     No                  6     RC
  Faba OR (2011) [36](#bju14417-bib-0036){ref-type="ref"}                                                Spain        1978--2002           141               19.9     No                  5     RC
  Badalato G (2012) [37](#bju14417-bib-0037){ref-type="ref"}, [\*](#bju14417-note-0002){ref-type="fn"}   USA          1990--1999           90                24.4     No                  6     RC
  Badalato G (2012) [37](#bju14417-bib-0037){ref-type="ref"}, [\*](#bju14417-note-0002){ref-type="fn"}   USA          2000--2010           259               10.0     No                  6     RC
  Green DA (2012) [38](#bju14417-bib-0038){ref-type="ref"}                                               USA          NR                   201               10.4     Yes                 6     RC
  Xie HY (2012) [39](#bju14417-bib-0039){ref-type="ref"}                                                 China        2003--2011           248               17.7     Yes                 5     RC
  Kwon D (2012) [40](#bju14417-bib-0040){ref-type="ref"}                                                 Korea        1999--2010           406               3.0      No                  7     TUR
  Branchereau J (2013) [41](#bju14417-bib-0041){ref-type="ref"}                                          France       1994--2009           108               36.1     Yes                 5     TUR
  Brimo F (2013) [42](#bju14417-bib-0042){ref-type="ref"}                                                Canada/USA   2004--2012           86                12.8     Yes                 6     TUR
  Bolenz C (2013) [43](#bju14417-bib-0043){ref-type="ref"}                                               EU           2000--2006           111               18.0     Yes                 6     TUR
  Levidou G (2013) [44](#bju14417-bib-0044){ref-type="ref"}                                              Greece       1985--1995           115               22.6     No                  5     NR
  Olsson H (2013) [45](#bju14417-bib-0045){ref-type="ref"}                                               Sweden       1992--2001           211               7.6      Yes                 6     TUR
  Kaimakliotis HZ (2014) [46](#bju14417-bib-0046){ref-type="ref"}                                        USA          2008--2013           308               9.1      No                  5     RC
  Prelevic R (2014) [47](#bju14417-bib-0047){ref-type="ref"}                                             Serbia       2002--2012           233               69.5     Yes                 4     RC
  Svatek RS (2014) [48](#bju14417-bib-0048){ref-type="ref"}                                              USA          2000--2008           545               9.0      No                  4     RC
  Goldsmith B (2014) [49](#bju14417-bib-0049){ref-type="ref"}                                            USA          1987--2010           315               12.7     No                  6     RC
  Go H (2015) [10](#bju14417-bib-0010){ref-type="ref"}                                                   Korea        1996--2006           274               2.9      Yes                 6     TUR
  Pietzak EJ (2015) [50](#bju14417-bib-0050){ref-type="ref"}                                             USA          1990--2009           275               12.0     No                  5     RC
  Miyake M (2015) [11](#bju14417-bib-0011){ref-type="ref"}                                               Japan        1998--2013           106               38.7     No                  6     TUR
  Patschan O (2015) [12](#bju14417-bib-0012){ref-type="ref"}                                             Sweden       1997--2003           156               24.2     No                  7     TUR
  Weiss BE (2015) [13](#bju14417-bib-0013){ref-type="ref"}                                               USA          1977--2009           120               4.2      No                  6     TUR
  Fukumoto K (2016) [14](#bju14417-bib-0014){ref-type="ref"}                                             Japan        1994--2013           116               25.9     Yes                 6     TUR
  Haas CR (2016) [15](#bju14417-bib-0015){ref-type="ref"}                                                USA          1990--2012           117               8.5      No                  7     RC
  Li G (2016) [16](#bju14417-bib-0016){ref-type="ref"}                                                   China        2003--2014           206               27.7     Yes                 7     RC
  Sha N (2016) [17](#bju14417-bib-0017){ref-type="ref"}                                                  China        2006--2010           155               21.9     Yes                 6     TUR
  Lucca I (2016) [51](#bju14417-bib-0051){ref-type="ref"}                                                EU           2001--2014           350               9.7      Yes                 6     RC
  Ukai R (2017) [18](#bju14417-bib-0018){ref-type="ref"}                                                 Japan        2000--2012           86                17.4     Yes                 4     TUR

EU, European Union; LVI, lymphovascular invasion; NOS, Newcastle--Ottawa score; NR, not reported; RC, radical cystectomy; TUR, transurethral resection. **\***Two different cohorts of patients treated from 1990 to 1999 and from 2000 to 2010 analysed in a single study.
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###### 

Pathological characteristics of the eligible studies included in the systematic review

  Study and year                                                    cT stage (%)   High grade or G2--3 (%)   Muscle in TUR speci men (%)   Re‐staging TUR (%)   Intravesical adjuvant treatment   NAC    AC     Upstaging (pT3--4 at RC) (%)   pN stage at RC (%)   Median follow‐up (months)                        
  ----------------------------------------------------------------- -------------- ------------------------- ----------------------------- -------------------- --------------------------------- ------ ------ ------------------------------ -------------------- --------------------------- ------ ------ ------ ------
  Andius P (2007) [28](#bju14417-bib-0028){ref-type="ref"}          100            0                         0                             96.0                 88                                17     1      3                              NR                   NR                          NR     NR     NR     NR
  Kassouf W (2007) [29](#bju14417-bib-0029){ref-type="ref"}         17.0           54.0                      29                            100                  NR                                NR     NR     NR                             NR                   64                          NR     NR     NR     32
  Herr HW (2008) [30](#bju14417-bib-0030){ref-type="ref"}           0              57.0                      43                            NR                   100                               100    NR     NR                             NR                   100                         0      NR     NR     86
  Weizer AZ (2009) [31](#bju14417-bib-0031){ref-type="ref"}         100            0                         0                             NR                   100                               24.2   NR     NR                             NR                   excl                        NR     13.7   8.4    45.6
  Cho KS (2009) [32](#bju14417-bib-0032){ref-type="ref"}            100            0                         0                             97.4                 NR                                26.3   62     23                             NR                   NR                          NR     NR     NR     35
  Streeper N (2009) [33](#bju14417-bib-0033){ref-type="ref"}        5.8            65.0                      29                            NR                   NR                                NR     NR     NR                             NR                   excl                        11.3   37.9   NR     NR
  Seo HK (2010) [34](#bju14417-bib-0034){ref-type="ref"}            100            0                         0                             76.0                 100                               NR     100    0                              NR                   NR                          NR     NR     NR     48.6
  Font A (2011) [35](#bju14417-bib-0035){ref-type="ref"}            0              3.0                       97                            NR                   100                               NR     NR     NR                             NR                   100                         NR     NR     NR     45
  Faba OR (2011) [36](#bju14417-bib-0036){ref-type="ref"}           40.0           39.0                      21                            93.6                 NR                                NR     NR     NR                             NR                   NR                          5.7    NR     13.4   42.5
  Badalato G (2012) [37](#bju14417-bib-0037){ref-type="ref"}        100            0                         0                             NR                   31                                NR     NR     NR                             NR                   NR                          NR     NR     NR     NR
  Badalato G (2012) [37](#bju14417-bib-0037){ref-type="ref"}        100            0                         0                             NR                   47.5                              NR     NR     NR                             NR                   NR                          NR     NR     NR     NR
  Green DA (2012) [38](#bju14417-bib-0038){ref-type="ref"}          50.2           49.8                      0                             98.5                 NR                                NR     35.3   NR                             excl                 NR                          35.4   18.9   NR     
  Xie HY (2012) [39](#bju14417-bib-0039){ref-type="ref"}            47.0           53.0                      0                             87.0                 NR                                NR     NR     NR                             NR                   excl                        NR     NR     NR     NR
  Kwon D (2012) [40](#bju14417-bib-0040){ref-type="ref"}            100            0                         0                             59.4                 NR                                NR     NR     100                            0.2                  excl                        NR     NR     NR     76.9
  Branchereau J (2013) [41](#bju14417-bib-0041){ref-type="ref"}     100            0                         0                             100                  100                               72.2   0.1    100                            0.1                  NR                          NR     NR     NR     47.8
  Brimo F (2013) [42](#bju14417-bib-0042){ref-type="ref"}           100            0                         0                             NR                   74                                0      NR     NR                             NR                   NR                          NR     NR     NR     29
  Bolenz C (2013) [43](#bju14417-bib-0043){ref-type="ref"}          68.4           31.5                      0                             81.1                 NR                                NR     5.3    22.4                           27.6                 NR                          NR     NR     NR     30
  Levidou G (2013) [44](#bju14417-bib-0044){ref-type="ref"}         63.5           T2--3: 36.5               47.8                          NR                   NR                                33.6   NR     excl                           NR                   NR                          NR     NR            
  Olsson H (2013) [45](#bju14417-bib-0045){ref-type="ref"}          100            0                         0                             100                  NR                                14.7   NR     18.5                           0                    excl                        NR     NR     NR     60
  Kaimakliotis HZ (2014) [46](#bju14417-bib-0046){ref-type="ref"}   0              100                       0                             NR                   NR                                NR     NR     NR                             NR                   22.1                        14.6   43.5   29.2   30
  Prelevic R (2014) [47](#bju14417-bib-0047){ref-type="ref"}        24.9           75.1                      0                             100                  NR                                NR     NR     NR                             NR                   excl                        NR     56.6   NR     NR
  Svatek RS (2014) [48](#bju14417-bib-0048){ref-type="ref"}         40.9           41.7                      17                            NR                   NR                                NR     NR     NR                             NR                   36.9                        NR     NR     15.8   49.3
  Goldsmith B (2014) [49](#bju14417-bib-0049){ref-type="ref"}       13.0           64.1                      23                            NR                   NR                                NR     NR     NR                             NR                   excl                        NR     45.6   25.7   NR
  Go H (2015) [10](#bju14417-bib-0010){ref-type="ref"}              100            0                         0                             50.4                 NR                                NR     5.9    38.3                           NR                   NR                          NR     NR     NR     NR
  Pietzak EJ (2015) [50](#bju14417-bib-0050){ref-type="ref"}        0              100                       0                             NR                   100                               NR     NR     NR                             NR                   8.7                         NR     45.6   30.2   23.2
  Miyake M (2015) [11](#bju14417-bib-0011){ref-type="ref"}          100            0                         0                             100                  100                               12     13.0   54.0                           NR                   NR                          NR     NR     NR     23
  Patschan O (2015) [12](#bju14417-bib-0012){ref-type="ref"}        100            0                         0                             100                  NR                                60.3   3.2    25.6                           NR                   NR                          NR     NR     NR     78
  Weiss BE (2015) [13](#bju14417-bib-0013){ref-type="ref"}          100            0                         0                             100                  NR                                NR     19.2   80.8                           NR                   NR                          NR     NR     NR     53
  Fukumoto, K (2016) [14](#bju14417-bib-0014){ref-type="ref"}       100            0                         0                             100                  NR                                NR     13.8   73.3                           0                    NR                          NR     NR     NR     53
  Haas CR (2016) [15](#bju14417-bib-0015){ref-type="ref"}           100            0                         0                             NR                   NR                                42.7   0.0    100                            NR                   NR                          NR     12.8   18.8   60.7
  Li G (2016) [16](#bju14417-bib-0016){ref-type="ref"}              100            0                         0                             41.7                 NR                                NR     NR     NR                             NR                   NR                          NR     NR     NR     NR
  Sha N (2016) [17](#bju14417-bib-0017){ref-type="ref"}             100            0                         0                             39.4                 NR                                NR     97.4   NR                             NR                   NR                          NR     NR     78.4   
  Lucca I (2016) [51](#bju14417-bib-0051){ref-type="ref"}           29.0           71.0                      0                             79.0                 NR                                NR     NR     NR                             NR                   NR                          NR     NR     NR     NR
  Ukai R (2017) [18](#bju14417-bib-0018){ref-type="ref"}            100            0                         0                             100                  91                                NR     4.7    46.5                           NR                   NR                          NR     NR     NR     49

AC, adjuvant chemotherapy; adj: adjuvant; CT: chemotherapy, excl: excluded, NAC: neoAC, NR: not reported, RC: radical cystectomy, TUR: transurethral resection.
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Meta‐Analysis {#bju14417-sec-0013}
-------------

### Association of LVI in cT1 TUR Specimens with Disease Recurrence {#bju14417-sec-0014}

The impact of LVI on disease recurrence was investigated in six studies including 1 412 patients treated with TURBT for cT1 BCa. The forest plot (Fig. [2](#bju14417-fig-0002){ref-type="fig"}) shows that LVI was significantly associated with disease recurrence (pooled HR 1.97, 95% CI: 1.47--2.62; *z* = 4.61). The Cochrane *Q* test (χ^2^ = 2.06; *P* = 0.841) and *I* ^2^ test (*I* ^2^ = 0.0%) did not show any significant heterogeneity. The funnel plot did not identify any study over the pseudo 95% CI (Fig. [S1](#bju14417-sup-0001){ref-type="supplementary-material"}).

![Forest plot showing the association between lymphovascular invasion and disease recurrence in studies including patients treated with transurethral resection for non‐muscle‐invasive bladder cancer. HR, hazard ratio; RFS, recurrence‐free survival.](BJU-123-11-g002){#bju14417-fig-0002}

### Association of LVI in cT1 TUR Specimens with Disease Progression {#bju14417-sec-0015}

The impact of LVI on disease progression was investigated in nine studies including 1334 patients treated with TURBT for cT1 BCa. The forest plot (Fig. [3](#bju14417-fig-0003){ref-type="fig"}) shows that LVI was significantly associated with disease progression (pooled HR 2.95, 95% CI: 2.11--4.13; *z* = 6.30). The Cochrane *Q* test (χ^2^ = 3.15; *P* = 0.925) and *I* ^2^ test (*I* ^2^ = 0.0%) did not show any significant heterogeneity. The funnel plot did not identify any study over the pseudo 95% CI (Fig. [S2](#bju14417-sup-0002){ref-type="supplementary-material"}).

![Forest plot showing the association between lymphovascular invasion and disease progression in studies including patients treated with transurethral resection for non‐muscle‐invasive bladder cancer. HR, hazard ratio; PFS, progression‐free survival.](BJU-123-11-g003){#bju14417-fig-0003}

### Association of LVI in cT1--2 TUR Specimens with Upstaging at RC {#bju14417-sec-0016}

The impact of LVI on upstaging after RC was investigated in seven studies including 1710 patients treated with TURBT for cT1--T2 BCa. The forest plot (Fig. [4](#bju14417-fig-0004){ref-type="fig"}) shows that LVI was significantly associated with upstaging after RC (pooled HR 2.39, 95% CI: 1.45--3.96; *z* = 3.40) in all of the seven studies. Subgroup analysis showed that LVI was not significantly associated with upstaging after RC in studies evaluating cT2 patients alone (pooled HR 1.25, 95% CI: 0.35--4.44; *z* = 0.35), but it was significantly associated in studies evaluating patients with cT1--2 disease together (pooled HR 3.08, 95% CI: 1.99--4.78; *z* = 3.67). The Cochrane *Q* test (χ^2^ = 12.93; *P* = 0.044) and *I* ^2^ test (*I* ^2^ = 53.6%) showed significant heterogeneity. The funnel plot identified one study over the pseudo 95% CI (Fig. [S3](#bju14417-sup-0003){ref-type="supplementary-material"}).

![Forest plot showing the association between lymphovascular invasion and disease upstaging in studies including patients treated with transurethral resection and subsequently radical cystectomy for organ‐confined (≤cT2) bladder cancer. OR, odds ratio.](BJU-123-11-g004){#bju14417-fig-0004}

Discussion {#bju14417-sec-0017}
==========

Non‐muscle invasive BCa is a disease with highly variable behaviour and outcome. Patients with high‐risk T1 BCa have a greater risk of disease recurrence and progression compared with patients with T1 BCa without high‐risk features [3](#bju14417-bib-0003){ref-type="ref"}. The inherently heterogeneous course of T1 high grade/G3 disease makes this entity of NMIBC challenging to treat. An accurate risk stratification would allow the identification of those patients who should receive intensified therapies, such as early RC and preoperative systemic therapy, with the attempt to control micrometastatic disease. LVI is a histological feature of biologically and clinically aggressive BCa; it is associated with poor oncological outcomes if detected in RC specimens [5](#bju14417-bib-0005){ref-type="ref"}, [6](#bju14417-bib-0006){ref-type="ref"}, [7](#bju14417-bib-0007){ref-type="ref"}, [8](#bju14417-bib-0008){ref-type="ref"} as well as in patients with upper tract urothelial carcinoma [52](#bju14417-bib-0052){ref-type="ref"}. In non‐seminomatous testicular germ cell cancer, LVI presence upstages the tumour according to the TNM classification [53](#bju14417-bib-0053){ref-type="ref"}.

In the present study, a systematic review and meta‐analysis was conducted to assess the role of LVI in TUR specimens, to investigate its prognostic impact on disease recurrence and progression in patients with NMIBC and to evaluate its predictive value for upstaging at RC in patients with organ‐confined disease. We identified 6194 patients treated with TUR, for whom LVI status was evaluated in 33 studies. Overall, LVI was reported in 17.3% of cases and in 15% of patients in studies analysing only patients with ≤cT1 stage. We found that, in patients with NMIBC, the presence of LVI at TUR doubled the risk of developing disease recurrence (pooled HR 1.97, 95% CI: 1.47--2.62) and increased the risk of disease progression to MIBC threefold (pooled HR 2.95, 95% CI: 2.11--4.13) compared with patients without LVI.

The currently recommended scoring models for individualized prediction of disease recurrence and progression are the European Organization for Research and Treatment of Cancer (EORTC) \[3\] and the Spanish Urological Club for Oncological Treatment (CUETO) [54](#bju14417-bib-0054){ref-type="ref"} risk tables. The two scoring models are based on the most relevant clinical and pathological predictors, sex, age, tumour stage and grade, number of tumours, size, carcinoma *in situ* and prior recurrence rate. These tools aim to help in personalized risk assessment, thereby guiding clinical decision‐making regarding follow‐up and therapy; however, an external validation of these scores exhibited poor discrimination of both tools regarding disease recurrence and progression [55](#bju14417-bib-0055){ref-type="ref"}. Additional factors not included in the EORTC or the CUETO models might enhance their usefulness. Hydronephrosis as well as micropapillary or neuroendocrine variant histology could help identify patients who are likely to need multimodal intensified therapy [56](#bju14417-bib-0056){ref-type="ref"}.

An additional key feature with which to identify patients with aggressive biology and poor outcomes is LVI. The invasion of the numerous blood and lymphatic vessels in the lamina propria allow early haematogenous and lymphatic cancer cell dissemination [57](#bju14417-bib-0057){ref-type="ref"}. In this context, LVI might indicate a histological pattern associated with a higher propensity to muscle‐invasive, non‐organ‐confined disease and micrometastases. We found that LVI was associated with a more than double risk of upstaging after RC. Unfortunately, we could not identify any study analysing the impact of LVI on upstaging in NMIBC at TURBT; however, subgroup analysis showed that the association between LVI and upstaging was even higher in cT1--2 patients, while it was not significant in patients with cT2 disease. These results suggest that the presence of LVI is an independent prognostic factor of upstaging in cT1 disease, while it lost its significance in cT2 stage disease because of the greater aggressiveness of the cT2 disease itself. Thus, cT1 disease with LVI should be considered as an intermediate stage between cT1 and cT2 disease in terms of prognosis, thereby prognostically upstaging cT1. Whether this is because of the micrometastatic potential conferred by LVI remains to be determined. Further prospective studies could assess the indication to perform neoadjuvant systemic therapy prior to RC in patients with LVI in cT1 BCa. In patients with cT2 LVI, this has been already widely suggested [58](#bju14417-bib-0058){ref-type="ref"}, [59](#bju14417-bib-0059){ref-type="ref"}.

Critical for LVI assessment is the quality of the specimen. The rate of muscle presence in the specimen, which could be seen as a surrogate of quality of resection, ranged from 31% to 100% in the studies included in the review. Similarly, the rate of re‐staging TUR was often not reported and varied considerably among one‐third of studies included in the review. The depth of resection, the specimen size as well as the experience of the surgeon might influence the detection of LVI in the TUR specimen, the therapeutic decision‐making process and, therefore, the course of the disease.

The present meta‐analysis has some limitations. Only non‐randomized observational studies were included and all of them had a retrospective design. Furthermore, patients could not be controlled for the quality of the TUR, effect of repeat TUR and follow‐up schedules. In addition, a limitation was the different type of drug used for adjuvant therapy (BCG, mitomycin C, doxorubicin, epirubicin, etc.), the different treatment schedule and maintenance drug adopted. In addition, some studies did not provide a definition of LVI, usually described as the unequivocal presence of tumour cells within an endothelium‐lined space, with no underlying muscular walls [60](#bju14417-bib-0060){ref-type="ref"}. Studies separately analysing the combination of vascular and lymphatic invasion by tumour cells were excluded from the analysis as they may represent another disease entity, leading to heterogeneity. Pathology was performed by various pathologists and no study provided a centralized pathology assessment. Most of the studies did not report the long‐term oncological outcomes; this could have significantly influenced the results of the present meta‐analysis. Studies that did not identify independent predictors of outcomes are less likely to be published. All these limitations introduce a selection bias, as shown in the risk‐of‐bias assessments. Finally, in the analysis of the impact of LVI on upstaging (Figs [4](#bju14417-fig-0004){ref-type="fig"} and [S3](#bju14417-sup-0003){ref-type="supplementary-material"}) a significant heterogeneity was detected. This could be related to the different surgical indication to perform RC related to centres' and surgeons' preference according to the clinical features of each patient and to treatments other than RC not considered in this analysis, such as partial cystectomy and trimodality therapy.

In conclusion, despite the limitations inherent to the retrospective nature of studies included, the results of the present meta‐analysis suggest that LVI at TUR is a significant prognostic factor for disease recurrence and progression in patients with NMIBC. Furthermore, LVI seems to have a strong impact on upstaging. The assessment of LVI should be standardized and included in the TNM system. This readily accessible histological feature, together with other factors, may help clinicians to design more personalized management strategies helping in the decision‐making regarding intensified therapy, counselling and follow‐up for patients with NMIBC.
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BCa

:   bladder cancer

CUETO

:   Spanish Urological Club for Oncological Treatment

EORTC

:   European Organization for Research and Treatment of Cancer () \[3\]

HR

:   hazard ratio

LVI

:   lymphovascular invasion

MIBC

:   carcinoma invading the bladder muscle

NMIBC

:   non‐muscle invasive bladder cancer

PRISMA

:   Preferred Reporting Items for Systematic reviews and Meta‐Analyses

RC

:   radical cystectomy

ROBINS‐I

:   Risk Of Bias In Non‐randomised Studies ‐ of Interventions

TURBT

:   transurethral resection of the bladder tumour

TUR

:   transurethral resection
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**Fig. S1** Funnel plot showing the effect estimates of individual studies for the analysis of the impact of lymphovascular invasion on disease recurrence in patients treated with transurethral resection for non‐muscle‐invasive bladder cancer.
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Click here for additional data file.
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**Fig. S2** Funnel plot showing the effect estimates of individual studies for the analysis of the impact of lymphovascular invasion on disease progression in patients treated with transurethral resection for non‐muscle‐invasive bladder cancer.
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Click here for additional data file.
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**Fig. S3** Funnel plot showing the effect estimates of individual studies for the analysis of the impact of lymphovascular invasion on disease upstaging in patients treated with transurethral resection and consequently to radical cystectomy for organ‐confined (≤cT2) bladder cancer.
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Click here for additional data file.
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**Table S1** PRISMA‐P (Preferred Reporting Items for Systematic review and Meta‐Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol.
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Click here for additional data file.
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**Table S2** The Risk of Bias In Non‐randomized Studies -- of Interventions (ROBINS‐I) assessment of individual studies for the analysis of the impact of lymphovascular invasion on disease recurrence in patients treated with transurethral resection for non‐muscle‐invasive bladder cancer.
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Click here for additional data file.
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**Table S3** The Risk of Bias In Non‐randomized Studies -- of Interventions (ROBINS‐I) assessment of individual studies for the analysis of the impact of lymphovascular invasion on disease progression in patients treated with transurethral resection for non‐muscle‐invasive bladder cancer.
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Click here for additional data file.
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**Table S4** The Risk of Bias In Non‐randomized Studies -- of Interventions (ROBINS‐I) assessment of individual studies for the analysis of the impact of lymphovascular invasion on disease upstaging in patients treated with transurethral resection for non‐muscle‐invasive bladder cancer.
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Click here for additional data file.
